A detailed history of Capital Performance Advisors LLP transactions in Eli Lilly & CO stock. As of the latest transaction made, Capital Performance Advisors LLP holds 760 shares of LLY stock, worth $569,939. This represents 0.21% of its overall portfolio holdings.

Number of Shares
760
Previous 460 65.22%
Holding current value
$569,939
Previous $416,000 61.78%
% of portfolio
0.21%
Previous 0.16%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024

BUY
$772.14 - $960.02 $231,642 - $288,006
300 Added 65.22%
760 $673,000
Q2 2024

Aug 01, 2024

BUY
$724.87 - $909.04 $26,095 - $32,725
36 Added 8.49%
460 $416,000
Q1 2024

Apr 26, 2024

BUY
$592.2 - $792.28 $30,202 - $40,406
51 Added 13.67%
424 $329,000
Q4 2023

Feb 06, 2024

BUY
$525.19 - $619.13 $195,895 - $230,935
373 New
373 $217,000

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $713B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Capital Performance Advisors LLP Portfolio

Follow Capital Performance Advisors LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital Performance Advisors LLP, based on Form 13F filings with the SEC.

News

Stay updated on Capital Performance Advisors LLP with notifications on news.